BMO Capital raised the firm’s price target on Gilead (GILD) to $102 from $94 and keeps an Outperform rating on the shares. The firm cites a “consistent steady performance” from Gilead this quarter, which continues to show the reliable strength in its HIV business, the analyst tells investors in a research note. This is encouraging ahead of the company’s U.S. filing of lenacapavir for PrEP, BMO added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD: